Identification and characterization of UK-201844, a novel inhibitor that interferes with human immunodeficiency virus type 1 gp160 processing

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 10, 2007, Pages 3554-3561

  Blair, Wade S ^a,b   Cao, Joan ^a   Jackson, Lynn ^a   Jimenez, Judith ^a   Peng, Qinghai ^a   Wu, Hua ^a   Isaacson, Jason ^a   Butler, Scott L ^a   Chu, Alex ^a   Graham, Joanne ^a   Malfait, Anne Marie ^a   Tortorella, Micky ^a   Patick, Amy K ^a  

^a PFIZER INC   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 [2 (2,3 DIHYDRO 1 BENZOFURAN 5 YL)ETHYL]PIPERIDIN 3 YL] 2,2 DIPHENYLACETAMIDE; ANTIVIRUS AGENT; GLYCOPROTEIN GP 160; UK 201844; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; SEQUENCE ANALYSIS; VESICULAR STOMATITIS VIRUS; VIRION; VIRUS STRAIN; WESTERN BLOTTING;

ANTI-HIV AGENTS; BENZENEACETAMIDES; BENZOXAZINES; BLOTTING, WESTERN; CYTOPATHOGENIC EFFECT, VIRAL; DNA, RECOMBINANT; DRUG RESISTANCE, BACTERIAL; HELA CELLS; HIV CORE PROTEIN P24; HIV ENVELOPE PROTEIN GP160; HIV-1; HUMANS; PIPERIDINES; PROTEIN PROCESSING, POST-TRANSLATIONAL; VIRUS REPLICATION;

EID: 34948900842     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00643-07     Document Type: Article

References (26)

1. Blair, W. S., J. S. Isaacson, X. Li, J. Q. Cao, Q. Peng, G. F. Z. Kong, and A. K. Patick. 2005. A novel HIV-1 antiviral high throughput screening approach for the discovery of HIV-1 inhibitors. Antivir. Res. 65:107-117.
2. Cao, J., J. Isaacson, A. K. Patick, and W. S. Blair. 2005. A high-throughput human immunodeficiency virus type 1 (HIV-1) full-replication assay that includes HIV-1 Vif as an antiviral target. Antimicrob. Agents Chemother. 49:3833-3841.
3. De Clercq, E., N. Yamamoto, R. Pauwels, M. Baba, D. Schols, H. Nakashima, J. Balzarini, Z. Debyser, B. A. Murrer, D. Schwartz, D. Thornton, G. Bridger, S. Flicker, G. Henson, M. Abrams, and D. Picker. 1992. Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proc. Natl. Acad. Sci. USA 89:5286-5290.
4. DeJesus, E., D. Berger, M. Markowitz, C. Cohen, T. Hawkins, P. Ruane, R. Elion, C. Farthing, A. Cheng, B. Kearney, and the 183-0101 Study Team. 2006. The HIV integrase inhibitor GS-9137 (JTK-303) exhibits potent antiviral activity in treatment-naïve and experienced patients, abstr. 160LB. Thirteenth Conf. Retrovir. Oppor. Infect.
5. Dubay, J. W., S. R. Dubay, H.-J. Shin, and E. Hunter. 1995. Analysis of the cleavage site of the human immunodeficiency virus type 1 glycoprotein: requirement of precursor cleavage for glycoprotein incorporation. J. Virol. 69:4675-4682.
6. Fätkenheuer, G., A. L. Pozniak, M. Johnson, M. A. Plettenberg, S. Staszewski, I. M. Hoepelman, M. Saag, F. Goebel, J. Rockstroh, B. Dezube, T. M. Jenkins, C. Medhurst, J. F. Sullivan, C. Ridgway, S. Abel, M. Youle, and E. van der Ryst. 2004. Evaluation of dosing frequency and food effect on viral load reduction during short-term monotherapy with UK-427,857 a novel CCR5 antagonist, abstr. TuPeB4489. Fifteenth Int. AIDS Conf.
7. Hallenberger, S., V. Bosch, H. Angliker, E. Shaw, H.-D. Klenk, and W. Garten. 1992. Inhibition of furin-mediated cleavage activation of HIV-1 gp160. Nature 360:358-361.
8. Hanna, G., J. Lalezari, J. Hellinger, D. Wohl, T. Masterson, W. Fiske, J. Kadow, P. Lin, M. Giordano, R. Colonno, and D. Grasela. 2004. Antiviral activity, safety, and tolerability of a novel, oral small-molecule HIV-1 attachment inhibitor, BMS-488043, in HIV-1-infected subjects, abstr. 141. Eleventh Conf. Retrovir. Oppor. Infect.
9. Hendrix, C. 2004. Safety, pharmacokinetics and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. J. Acquir. Immune Defic. Syndr. 37:1253-1262.
10. Johnson, V. A., and R. E. Barrington. 1990. Infectivity assay, p. 71-76. In A. Aldovini and B. D. Walker (ed.), Techniques in HIV research. Stockton Press, New York, NY.
11. Jose, E. S., M. A. Munoz-Fernandez, and B. Alarcon. 1997. Megalomicin inhibits HIV-1 replication and interferes with gp160 processing. Virology 239:303-314.
12. Kowalski, M., J. Potz, L. Basiripour, T. Dorfman, W. C. Goh, E. Terwilliger, A. Dayton, C. Rosen, W. Haseltine, and J. Sodroski. 1987. Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. Science 237:1351-1355.
13. Kwong, P. D., R. Wyatt, J. Robinson, R. Sweet, W. J. Sodroski, and W. A. Hendrickson. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648-659.
14. Leonard, C. K., M. W. Spellman, L. Riddle, R. J. Harris, J. N. Thomas, and T. J. Gregory. 1990. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J. Biol. Chem. 265:10373-10382.
15. Little, S., G. Drusano, R. Schooley, H. Haas, P. Kumar, S. Hammer, D. McMahon, K. Squires, R. Asfour, D. Richman, J. Chen, A. Saah, R. Leavitt, D. Hazuda, B. Y. Nguyen, and the Protocol 004 Study Team. 2005. Antiretroviral effect of L-000870810, a novel HIV-1 integrase inhibitor, in HIV-1-infected patients, abstr. 161. Twelfth Conf. Retrovir. Oppor. Infect.
16. Martin, D., J. Jacobson, D. Schurmann, E. Osswald, J. Doto, C. Wild, and G. Allaway. 2005. PA-457, the first-in-class maturation inhibitor, exhibits antiviral activity following a single oral dose in HIV-1-infected patients, abstr. 159. Twelfth Conf. Retrovir. Oppor. Infect.
17. McCune, J. M., L. B. Rabin, M. B. Feinberg, M. Lieberman, J. C. Kosek, G. R. Reyes, and I. L. Weissman. 1988. Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus. Cell 53:55-67.
18. Morales-Ramirez, J. O., H. Teppler, C. Kovacs, R. T. Steigbigel, D. Cooper, R. L. Liporace, R. Schwartz, L. Wenning, J. Zhao, L. Gilde, R. Isaacs, and B.-Y. Nguyen. 2005. Antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, in ART-naïve HIV-infected patients, abstr. LBPS1/6. 10th Eur. AIDS Conf.
19. Moulard, M., and E. Decroly. 2000. Maturation of HIV envelope glycoprptein precursors by cellular endoproteases. Biochim. Biophys. Acta 1469:121-132.
20. Pal, R., R. C. Gallo, and M. G. Sarngadharan. 1988. Processing of the structural proteins of human immunodeficiency virus type 1 in the presence of monensin and cerulenin. Proc. Natl. Acad. Sci. USA 85:9283-9286.
21. Pal, R., G. M. Hoke, and M. G. Sarngadharan. 1989. Role of oligosaccharides in the processing and maturation of envelope glycoproteins of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 86:3384-3388.
22. Walker, B. D., M. Kowalski, W. C. Goh, K. Kozarsky, M. Krieger, C. Rosen, L. Rohrschneider, W. A. Haseltine, and J. Sodroski. 1987. Inhibition of human immunodeficiency virus syncytium formation and virus replication by castanospermine. Proc. Natl. Acad. Sci. USA 84:8120-8124.
23. Wang, T., Z. Zhang, O. B. Wallace, M. Deshpande, H. Fang, Z. Yang, L. M. Zadjura, D. L. Tweedie, S. Huang, F. Zhao, S. Ranadive, B. S. Robinson, Y.-F. Gong, K. Ricarrdi, T. P. Spicer, C. Deminie, R. Rose, H. Wang, W. S. Blair, P.-Y. Shi, P.-F. Lin, R. J. Colonno, and N. A. Meanwell. 2003. Discovery of 4-benzoyl-1-[(4-methoxyl-1H-pyrrolo[2,3-b]pyridine-3-yl)oxoacetyl]-2-(R) -methylpiperazine (BMS-378806): a novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions. J. Med. Chem. 46:4236-4239.
24. Weislow, O. S., R. Kiser, D. L. Fine, J. Bader, R. H. Shoemaker, and M. R. Boyd. 1989. New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J. Natl. Cancer Inst. 81:577-586.
25. Wild, C., N. Kilgore, M. Reddick, F. Li, K. Salzwedel, C. Matallana, G. Allaway, and D. Martin. 2003. PA-457 is a small molecule inhibitor of HIV-1 budding/maturation that potently inhibits replication of virus isolates resistant to all classes of approved drugs, abstr. 14. Tenth Conf. Retrovir. Oppor. Infect.
26. Yeni, P. G., S. M. Hammer, M. S. Hirsch, M. S. Saag, M. Schechter, C. C. J. Carpenter, M. A. Fischl, J. M. Gatell, B. G. Gazzard, D. M. Jacobsen, D. A. Katzenstein, J. S. G. Montaner, D. D. Richman, R. T. Schooley, M. A. Thompson, S. Vella, and P. A. Volberding. 2004. Treatment for adult HIV infection: 2004 recommendations of the international AIDS society-USA panel. JAMA 292:251-265.